Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Understanding the mRNA Therapeutics Market's -8.6% Decline: Insights from BCC Research

      BCC_Research_Logo

      News provided by

      BCC Research LLC

      Apr 10, 2024, 10:20 ET

      Share this article

      Share this article


      mRNA, the messenger molecules transferring genetic instructions from DNA to ribosomes, is now at the forefront of pharmaceutical innovation. With mRNA therapeutics and vaccines emerging as game-changers, they offer a promising avenue for treating not only COVID-19 but also a spectrum of diseases, including infectious diseases, cancer, and genetic disorders.

      BOSTON, April 10, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for mRNA: Therapeutics and Global Markets is estimated to decrease from $33 billion in 2023 to reach $21 billion by 2028, at a compound annual growth rate (CAGR) of -8.6% from 2023 through 2028."

      This report delves into the mRNA therapeutics market, exploring various types of mRNA and their applications in therapy. It provides detailed insights into patent analysis and clinical trial analysis of mRNA, along with highlighting trends and dynamics influencing the market during the study period. The analysis extends to market projections up to 2028 and profiles key market players. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW), with estimations spanning until 2028. Additionally, BCC Research offers a comprehensive overview of industry acquisitions and strategic alliances from January 2020 to December 2022, identifying emerging trends in this activity. 

      Explore the full report on the burgeoning mRNA Therapeutics Markets for comprehensive insights and forecasts – click here to Learn More. 

      Market Drivers for mRNA Therapeutics

      Increasing Pandemics and Epidemics: The global landscape has witnessed a surge in pandemics and epidemics, prompting a heightened demand for innovative therapeutic solutions. mRNA-based vaccines and drugs have emerged as pivotal tools for swiftly responding to emerging infectious diseases, notably exemplified by their effectiveness against COVID-19. In response, governments and healthcare organizations worldwide are directing investments toward mRNA research, recognizing its potential to combat health crises effectively.

      Increasing Uptake of Vaccines: The remarkable success of mRNA vaccines like Pfizer-BioNTech and Moderna in combating COVID-19 has underscored the transformative potential of this technology. Consequently, public awareness and acceptance of mRNA-based vaccines have seen a significant uptick, fostering greater confidence in their efficacy and safety. This growing acceptance has not only propelled the widespread adoption of mRNA vaccines for COVID-19 but also laid the groundwork for their utilization against other diseases.

      Investment in mRNA Increasing: Biotech firms, research institutions, and pharmaceutical giants are funneling substantial investments into mRNA research and development initiatives. This funding is pivotal in supporting critical aspects such as clinical trials, manufacturing processes, and the scaling up of production for mRNA-based therapies. The surge in investment in mRNA technology is poised to drive innovation and broaden the scope of therapeutic applications, promising significant advancements in healthcare in the years to come.

      Request a Sample Copy of the mRNA: Therapeutics and Global Markets Report.

      Report Synopsis 

      Report Metrics

      Details

      Base year considered

      2022

      Forecast Period considered

      2023-2028

      Base year market size

      $60.0 billion

      Market Size Forecast

      $21.0 billion

      Growth Rate

      CAGR of -8.6% from 2023 to 2028

      Segment Covered

      By Type and Region

      Regions covered

      North America, Europe, Asia-Pacific and the Rest of the World (RoW)

      Key Market Drivers

      •  Increasing Pandemics and Epidemic

      •  Increasing Uptake of Vaccines

      •  Investment in mRNA Increasing

      •  Advantages of mRNA Drugs

      mRNA Therapeutics Markets Segmentation Analysis

      Segmentation by Type of Drugs

      Within the domain of mRNA therapeutics, two key categories emerge: prophylactic vaccines and therapeutic drugs. Prophylactic vaccines are pivotal in preventing specific diseases, leveraging the mRNA platform's agility for rapid development and adaptation, notably showcased by the success of mRNA-based COVID-19 vaccines like Pfizer-BioNTech and Moderna. These vaccines hold promise for addressing emerging infectious diseases swiftly. On the other hand, therapeutic drugs encompass a wide range of applications, from oncology to infectious diseases, genetic disorders, and autoimmune conditions. mRNA therapies offer tailored treatment options, including personalized cancer vaccines and targeted treatments for various ailments, capitalizing on the platform's versatility and efficacy.

      Regional Focus Areas Segmentation

      Different regions exhibit varying degrees of involvement and investment in mRNA therapeutics. North America stands as a prominent hub for research and development, benefitting from significant investments, robust clinical trial infrastructure, and favorable regulatory environments. Europe follows suit with collaborative efforts and increasing adoption of mRNA-based treatments. The Asia-Pacific region showcases growing interest and investment, particularly in countries like China and India, while the Middle East and Africa demonstrate emerging awareness and potential for market growth. South America is witnessing a rise in awareness and participation in mRNA clinical trials, indicating untapped market potential and opportunities for growth in the region. International collaborations play a crucial role across all regions, driving research and development efforts and shaping the future landscape of mRNA therapeutics.

      This report on mRNA Therapeutics and Global Markets provides comprehensive insights and analysis, addressing the following key questions:

      1. What is the projected market size and growth rate of the market?

        The mRNA therapeutics market is valued at $60 billion and it is growing at -8.6% during the forecasting period to reach $21 billion.

      2. What are the key factors driving the growth of the market?

        The key factors driving the growth are the increasing investment in the mRNA technology and the rise in pandemic and epidemics.

      3. What segments are covered in the market?

        The mRNA market has been studied by type and by region.

      4. By Application, which segment will dominate the market by the end of 2028?

        The COVID vaccine will decline yet still dominate the market, as it will become part of regular vaccination regime in developed countries.

      5. Which region has the highest market share in the market?

        North America holds the highest share in the market.

      Some of the Key Market Players Are:

      •  ARCTUR U.S. THERAPEUTICS INC.
      •  CUREVAC N.V.
      •  MERCK KGAA
      •  NUTCRACKER THERAPEUTICS
      •  STRAND THERAPEUTICS
      •  BIONTECH SE
      •  GENNOVA BIOPHARMACEUTICALS LTD.
      •  MODERNA INC.
      •  OMEGA THERAPEUTICS INC.
      •  VAXESS TECHNOLOGIES INC.

      Browse Related Reports:

      RNAi Drug Delivery: Technologies and Global Markets: This research report provides a comprehensive categorization of the nucleic acid drugs market, primarily focusing on two major product segments: conjugated and encapsulated nucleic acid drugs. Encapsulated drugs are further delineated by the types of non-viral vectors employed, including polymers, lipids, and other materials like inorganic substances and hybrid systems. Moreover, segmentation extends across molecule types, delivery modes, and therapeutic areas, distinguishing between therapeutic and research-based applications. Geographically, the market analysis spans North America, Europe, the Asia-Pacific region, and the Rest of the World (RoW), offering insights into regional trends and dynamics within the nucleic acid drugs industry.

      Directly Purchase a copy of the report with BCC Research.

      For further information or to make a purchase, please get in touch with [email protected]. 

      About BCC Research

      BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.

      Contact Us
      Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
      Email: [email protected],
      Phone: +1 781-489-7301
      For media inquiries, email [email protected]  or visit our media page for access to our market research library.
      Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

      Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

      SOURCE BCC Research LLC

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.